InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $2.670 0.47 (21.36%)+
Announcement
Release
22 Jan 2026 8:26AM
Price at Release
$2.200
Full Release
download
Summary
Cogstate Limited experienced significant growth in its clinical trial sales contracts during the first half of the financial year 2026, reporting a 105% increase to $41.7 million. The total revenue for the period reached $26.9 million, surpassing the company's guidance. Cogstate has diversified its revenue sources, with an increased focus on neurological conditions beyond Alzheimer's disease, which accounted for 45% of the new sales contracts. This diversification has enhanced the company's revenue quality and financial resilience. The total contracted future revenue for the group stands at $104.9 million. Cogstate is expanding its customer base through strategic investments in its sales process and team, and will announce its audited financial results on 19th February 2026.
Key Points
  • Cogstate Ltd reported strong growth in clinical trial sales contracts for 1H26.
  • Total sales contracts executed amounted to $41.7 million, a 105% increase over the previous period.
  • Total revenue for the period was $26.9 million, exceeding guidance.
  • Cogstate's revenue profile is increasingly diversified across multiple neurological conditions.
  • Future contracted revenue has increased to $104.9 million.
  • 45% of sales contracts were for non-Alzheimer's indications, showing diversification.
  • Alzheimer's disease trials contributed $15.8 million to sales contracts.
  • Cogstate has invested in a new sales process and team to expand its customer base.
  • The company plans to release its audited 1H26 financial results on 19th February 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.